Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 801640, 8 pages
http://dx.doi.org/10.1155/2014/801640
Research Article

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

1Department of Oncology, Third Affiliated Hospital of Harbin Medical University, 150 Ha Ping Road, Nangang District, Harbin, Heilongjiang Province 150086, China
2Department of Cardiac Surgery, Second Affiliated Hospital of Harbin Medical University, 246 Xue Fu Road, Nangang District, Harbin, Heilongjiang Province 150086, China
3Department of Pathology, The Third Affiliated Hospital of Harbin Medical University, 246 Haping Road, Nangang District, Harbin, Heilongjiang Province 150081, China
4Laboratory of Medical Genetics, Harbin Medical University, 194 Xue Fu Road, Nangang District, Harbin, Heilongjiang Province 150086, China

Received 26 August 2013; Revised 12 November 2013; Accepted 13 November 2013; Published 19 March 2014

Academic Editor: Maria Lina Tornesello

Copyright © 2014 Sun Xian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study. We found that the variant genotypes of 6007C > T polymorphisms significantly associated with the chemotherapy response. The 6007CC genotype carriers had a higher chance to be responder to chemotherapy (adjusted odd ratio = 2.77; 95% CI: 1.83–4.18; adjusted < 0.001). The 6007C > T polymorphisms and BMP-4 expression also affect the prognosis of NSCLC. Patients with high BMP-4 expression had a significantly higher chance to be resistant to chemotherapy than those with low BMP-4 expression (OR = 2.81; 95% CI: 1.23–6.44; ). The hazard ratio (HR) for 6007TT was 2.37 times higher than 6007CC ( ). In summary, the 6007C > T polymorphism of BMP-4 gene and BMP-4 tissue expression may be used as potential predictor for the chemotherapy response and prognosis of advanced NSCLC.